Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Christophe Parsy, PhD, Drug Discovery Business Development Director 2 April 2020 17h-17h45 – Paris & 11h-11h45 – New York 7 April 2020 20h-20h45 – Paris & 11h-11h45 – San Diego
Outsourcing drug discovery has become an overwhelmingly accepted approaches across the pharmaceutical industry from virtual biotech to large pharmaceutical companies as part of the globalization process. It does represent a cost-effective opportunity to access specialized technologies and expert scientist resources having a broad knowledge of pharmaceutical drug discovery development.
When it comes to outsourcing a project, quality, innovation, time and agility are key components of the selection process to build a trusted and long term relationship.
Key learning objectives
Introduction to a solution provider from hits finding to IND
Advantages of Drug discovery integrated provider vs silos approach
About our speaker Christophe Parsy
Christophe has acquired a broad knowledge of the pharmaceutical industry by working in various R&D environments from Research services provider to Biotech and large Pharma. Over the past 20 years, he lead major drug discovery projects from Hit to IND in Anti-infective (HIV, HCV) and Oncology. These resulted in clinical candidates IDX320, Samatasvir and Uprifosbuvir. He has a proven ability to lead and deliver clinical candidates in a cross-functional and multi-cultural environment with a track record of delivering high quality candidate in a fast-paced environment. Proactive leadership with a high degree of priority setting, he recently completed is training by obtaining an Executive MBA with specialization in Lean 6 Sigma, Strategy and Leadership. Christophe is author and co-inventor of 30 + patents and peer review publications. In May 2019, Christophe joined Oncodesign as Drug Discovery Business Development Director.